Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Inclusion Criteria: * Males or females age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Histologically confirmed locally advanced/unresectable or metastatic cutaneous melanoma * Measurable disease per RECIST version (v.) 1.1 criteria using imaging scans, OR peripheral lesions that can be adequately documented with a picture and a ruler even if they do not meet RECIST criteria * Patient must have failed prior alphaPD-1 or alphaPD-1 + alphaCTLA-4 therapy in the metastatic setting * V600BRAF wildtype tumor status confirmed by Clinical Laboratory Improvement Act (CLIA) approved lab * Hemoglobin \>= 8.0 g/dL * Whole blood cell count (WBC) \>= 2,000/mm\^3 * Absolute neutrophil count \>= 1,500/mm\^3 * Platelet count \>= 75,000/mm\^3 * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3.0 x institutional upper limit of normal (ULN), (=\< 5.0 x ULN in those with hepatic metastases) * Bilirubin =\< 1.5 x ULN; for subjects with documented/suspected Gilbert's disease, bilirubin =\< 3 x ULN * Albumin \>= 2.5 g/dl * Serum creatinine =\< 2.0 x upper limit of normal (ULN) * Left ventricular ejection fraction (LVEF) \>= 50% assessed by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan completed =\< 180 days (6 months) before initiation of protocol treatment * Patients must be willing to submit blood and tissue specimens for translational medicine studies * Patients must have a site of disease amenable to biopsy and…